Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients-Case Series and Literature Review.

Autor:	Popescu I; Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania., Croitoru VM; Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania.; Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania., Croitoru-Cazacu IM; Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania.; Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania., Dudau AM; Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania.; Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania., Herlea V; Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Pathology, Fundeni Clinical Institute, 022328 Bucharest, Romania., Dima SO; Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania., Croitoru AE; Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania.
Jazyk:	angličtina
Zdroj:	Journal of personalized medicine [J Pers Med] 2024 Jul 15; Vol. 14 (7). Date of Electronic Publication: 2024 Jul 15.
DOI:	10.3390/jpm14070750
Abstrakt:	Liquid biopsies can accurately identify molecular alterations in patients with colorectal cancer with high concordance with tissue analysis and shorter turnaround times. Circulating tumor (ct) DNA analysis can be used for diagnosing and monitoring tumor evolution in patients with metastatic colorectal cancer who are treated with EGFR inhibitors. In this article, we reported three clinical cases to illustrate the relevance of RAS mutations identified in ctDNA samples of patients with wild-type metastatic colorectal cancer who received an EGFR inhibitor plus chemotherapy as first-line treatment. The identification of RAS mutations in these patients is one of the most frequently identified mechanisms of acquired resistance. However, detecting a KRAS mutation via liquid biopsy can be caused by inter-tumor heterogeneity or it can be a false positive due to clonal hematopoiesis. More research is needed to determine whether ctDNA monitoring may help guide therapy options in metastatic colorectal cancer patients. We performed a literature review to assess the technologies that are used for analysis of RAS mutations on ctDNA, the degree of agreement between tissue and plasma and the importance of tissue/plasma discordant cases.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu